EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Different changes by acute electric footshock of opioid agonist and antagonist receptors in rat brain


Neuroscience Letters 49(3): 307-312
Different changes by acute electric footshock of opioid agonist and antagonist receptors in rat brain
Electric shock (ES) produces an opiate-like analgesia and catalepsy in rats, which may be mediated by endogenous opioid systems. The alterations of endogenous opioid receptors were investigated by an intermittent ES application. In a case of opiate agonists, [3H]dihydromorphine and [3H]D-Ala-Met-enkephalinamide, the application of ES produced a decrease of [3H]ligands' binding capacity. The binding capacity of the opiate antagonist [3H]naloxone was increased by the ES application. Endogenous putative opioid agonist- and antagonist-type receptors are differently regulated in vivo.

Accession: 005151974

PMID: 6093006

DOI: 10.1016/0304-3940(84)90307-0

Download PDF Full Text: Different changes by acute electric footshock of opioid agonist and antagonist receptors in rat brain



Related references

Allosteric changes in opioid receptors induced by the electric footshock. Research Communications in Substances of Abuse 6(4): 193-212, 1985

Bremazocine is an agonist at kappa-opioid receptors and an antagonist at mu-opioid receptors in the guinea-pig myenteric plexus. British Journal of Pharmacology 89(1): 245-249, 1986

Altered transition between agonist- and antagonist-favoring states of mu-opioid receptors in brain membranes with modified microviscosity. Journal of Neurochemistry 61(3): 1135-1140, 1993

Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo. European Journal of Pharmacology 498(1-3): 87-96, 2004

Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors. Journal of Medicinal Chemistry 29(10): 1855-1861, 1986

Stereostructure-activity relationship of opioid agonist and antagonist bivalent ligands. Evidence for bridging between vicinal opioid receptors. Journal of Medicinal Chemistry 28(9): 1140-1141, 1985

Dextrorphan binds to opioid receptors in guinea-pig brain membranes and is an antagonist at opioid receptors in myenteric plexus. Proceedings of the National Academy of Sciences of the United States of America 87(5): 1629-1632, 1990

Design and synthesis of chimeras as opioid delta/mu receptors agonist and CCKA/CCKB receptors antagonist. Abstracts of Papers American Chemical Society 221(1-2): MEDI 104, 2001

Acute delta- and kappa-opioid agonist pretreatment potentiates opioid antagonist-induced suppression of water consumption. Brain Research Bulletin 76(6): 597-604, 2008

SoRI9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate -GTP-Y-S binding at cloned opioid receptors. Society for Neuroscience Abstracts 27(1): 100, 2001